Neogenomics (NEO) Accumulated Expenses (2010 - 2026)

Neogenomics (NEO) has reported Accumulated Expenses for 17 consecutive years, with $12.7 million the latest figure, recorded in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $12.7 million, down 67.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.7 million (down 67.77% YoY), and the FY2025 annual result was $47.6 million, down 23.8% from the prior year.
• Accumulated Expenses was $12.7 million for Q1 2026 at Neogenomics, down from $47.6 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $62.4 million in Q4 2024 and troughed at $12.7 million in Q1 2026.
• Average Accumulated Expenses over 5 years is $35.6 million, with a median of $38.0 million recorded in 2022.
• Year-over-year, Accumulated Expenses surged 252.76% in 2023 and slumped 67.77% in 2026.
• Over 5 years, Accumulated Expenses stood at $15.1 million in 2022, then soared by 252.76% to $53.2 million in 2023, then advanced by 17.46% to $62.4 million in 2024, then fell by 23.8% to $47.6 million in 2025, then slumped by 73.25% to $12.7 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $12.7 million in Q1 2026, $47.6 million in Q4 2025, and $17.4 million in Q3 2025.